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CONNECTIVE TISSUE ACTIVATING PEPTIDE I11 
INDUCTION OF SYNTHESIS AND SECRETION OF 
PLASMINOGEN ACTIVATOR BY 
SYNOVIAL FIBROBLASTS 
CAROL GODOSHIAN RAGSDALE, C. WILLIAM CASTOR, 
DEDRA J .  ROBERTS, and KENNETH H. SWARTZ 
Connective tissue activating peptide I11 (CTAP- 
111) is a platelet factot that induces, in cultured connec- 
tive tissue cells, activities observed in chronic inflamma- 
tion. In this study we measured plasminogen activator 
secretion by synovial fibroblasts after stimulation by 
CTAP-111. Increased plasminogen activator secretion 
was observed 24-48 hours after stimulation. Induction 
was prevented by dexamethasone ( 10-9-10-7M), cyclo- 
heximide (1 pg/ml) and, variably, by aetinomycin D (0.3 
pglml), but not by cytosine arabinoside (10-4n/i. This is 
the first evidence that CTAP-I11 induces degradative as 
well as proliferative activity by connective tissue cells. 
Human platelets contain, and release during 
degranulation, a 9,278 dalton cationic protein, connec- 
tive tissue activating peptide 111 (CTAP-1111, which 
activates normal synovial and skin fibroblasts and 
chondrocytes (1,2). Such activation results in metabol- 
ic and secretory activities characteristic of inflamma- 
tory states and detectable in rheumatoid synovial cells 
in culture. Among its established actions, CTAP-I11 is 
mitogenic and stimulates glycosaminoglycan forma- 
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tion, glycolysis, cyclic AMP accumulation, and pros- 
taglandin E2 secretion (2-4). 
Increased neutral protease activity is common- 
ly observed in rheumatoid synovium, and its presence 
correlates with inflammatory injury (5). In the present 
study, we sought to determine whether synovial acti- 
vation by CTAP-I11 caused neutral protease induction. 
We report that this peptide enhanced secretion of 
plasminogen activator (PA) in both rheumatoid and 
non-rheumatoid cells. CTAP-111, heretofore recog- 
nized primarily as a “growth factor,” may play a role 
in tissue rcmodeling and promote tissue degradation in 
inflammatory sites. 
MATERIALS AND METHODS 
Fibroblast cultures. Human synovial membrane was 
obtained at  operation, minced, and tissue fragments distrib- 
uted in explant cultures in order to establish synovial fibro- 
blast cell lines (6). Some human synovial and skin fibroblast 
lines were recovered after storage at -80°C. Cell lines were 
confluent at passage and had been passaged at  least 3 times 
before use or storage. In patients from whom cell lines were 
obtained, the diagnosis of rheumatoid arthritis o r  other 
rheumatic diseases was confirmed by record review using 
American Rheumatism Association (7) or conventional clini- 
cal criteria. 
For each experiment, 2 x lo4 fibroblasts were added 
to  each well of a microtiter plate (Costar) in a volume of 0.1 
ml L- 15 medium containing 3% plasminogen-depleted fetal 
calf serum. In some experiments, wells were precoated with 
‘”I-fibrin. Cultures were set up in replicates of 8; cells were 
permitted to  attach and spread, and then mediators were 
added. In some experiments, drugs or latex particles ( 0 . 8 ~ )  
were added a t  the same time. Fibroblast cultures were 
incubated at 37°C for 4-48 hours: monolayers were then 
washed and the medium replaced with Dulbecco’s modified 
Eagle’s medium supplemented with 0.05% lactalbumin hy- 
drolysate (DME-LH) in prcparation for PA assay. 
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Table 1. Plasminogen-dependent fibrinolysis by synovial 
fibroblasts* 
Stimulus Patient cell line 
(diagnosis)t None %TAP-111 (n) MNL-CM (n) 
DM ( N l )  8.6 2 8.5 32.1 f 20 (5) 43.8 (2) 
CB (OA) 6.0 31.8 ( I )  50.9 ( I )  
GJ (PA) 15.0 29.5 (2) 38.6 ( I )  
EG (RA) 14.1 2 5.6 47.6 ? 5.4 (4) 64.3 2 11.6 (3) 
* Synovial fibroblasts were plated onto "'I-fibrin substrates and 
incubated in the presence or absence of connective tissue activating 
peptide 111 (CTAP-111, 20 pg/ml) or mononuclear leukocyte-condi- 
tioned medium (MNL-CM, 1:10) for 48 hours. Then plasminogen- 
dependent fibrinolysis was measured as described in Materials and 
Methods. Values are % "'1-fibrin solubilized, mean 2 SD. 
t NI  = normal; OA = osteoarthritis: PA = psoriatic arthritis; KA = 
rheumatoid arthritis. 
A1 1 10.9 2 8.7 34.4 t 17.9 43.9 4 23.9 
Preparation of mediators. CTAP-I11 was purified 
from outdated blood bank platelets and characterized as 
previously described (1). All preparations used contained a 
single protein as determined by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis. 
For  preparation of mononuclear leukocyte-condi- 
tioned medium (MNL-CM), mononuclear leukocytes were 
purified from heparinized whole blood by Ficoll-Hypaque 
centrifugation and incubated at  a concentration of 5 x lo6 
cells/rnl in serum-free KPMI 1640 medium (Gibco, Grand 
Island, NY) for 2 days at 37°C in 5% COz. This conditioned 
medium was stored at -20°C until use a t  a 1 : 10 dilution as  a 
positive control to stimulate fibroblast secretion of PA. 
Plasminogen activator assay. Fibroblast monolayers 
were washed after 4-48 hours of culture and the medium 
replaced with 0.2 ml DME-LH. PA activity of intact cells or 
fibroblast-conditioned medium (F-CM) was assayed using a 
'*'I-fibrin plate method as described below. 
When fibroblasts were cultured directly on the iodin- 
ated fibrin substrate, cell-associated PA activity was mea- 
sured over the 3-hour period following the change of medi- 
um. Plasminogen (2 pg) was added to  half the wells, and 
culture plates were incubated at 37°C. If PA was present, 
plasminogen was converted to  plasmin which solubilized the 
"'I-fibrin substrate. Aftcr 3 hours, the assay mixture con- 
taining iodinated fibrin split products was recovered and 
counted. The substrate in 12 wells that had contained only 
medium was digested with trypsin and counted to determine 
total radioactivity. Fibrinolysis was expressed as  the per- 
centage of the substrate solubilized during the assay period 
and was corrected for radioactivity solubilized in the ab- 
sence of enzyme (1-3%). Plasminogen, in the absence of PA, 
produced no added fibrinolysis, nor did streptokinase in the 
absence of plasminogen. Streptokinase-activated plasrnino- 
gen solubilized more than 90% of the substrate. Fibrinolysis 
of replicate cultures varied by 15%. 
When fibroblasts were cultured in uncoated wells, it 
was possible to assay secreted PA in F-CM. Prior to the 
assay, cultures were incubated in DME-LH for 24 hours at 
37"C, then the CM was collected. Aliquots of 10-50 p1 were 
added to 'Z51-fibrin-coated wells and diluted to a total 
volume of 0.2 ml in 0.1M Tris-HCI, p H  8.0, with or  without 2 
p g  plasminogen. Plates were then incubated for 3 hours and 
fibrinolysis was determined as described for the assay using 
intact cells. 
Human fibrinogen (Calbiochern, San Diego, CA) was 
purified, depleted of .plasminogen, and iodinated using a 
chloramine T method (8). '*'I-fibrin substrates were pre- 
pared in microtiter wells using the method of Klimetzek and 
Sorg (9). Plasminogen was purified from outdated plasma by 
lysine-Sepharose chromatography (10). 
RESULTS 
CTAP-111-induced PA secretion. All fibrinolysis 
observed was plasminogen-dependent. PA activity 
was easily detectcd in both rheumatoid and non- 
rheumatoid cell lines; both intact cells and conditioned 
medium showed activity. PA activity of unstimulated 
cells varied from week to week and from cell line to 
cell line by as much as eightfold. Baseline enzyme 
activity did not appear to be influenced by the number 
of cell passages. 
Addition of CTAP-I11 to cultures resulted in 
enhanced PA activity in 21 of 24 experiments in 8 of 9 
cell lines assayed at different times over a 1-year 
period (Tables 1 and 2). Unstimulated fibroblasts 
cultured on 12'I-fibrin solubilized 10.9 * 8.7% of the 
substrate, and CTAP-111-stimulated cells solubilized 
34.4 * 17.9% (P  < 0.01) (Table 1). Fibroblasts stimu- 
lated by conditioned medium from MNL cultures 
solubilized 43.9 t 23.9% of the substrate (Table 1). 
Table 2. Plasminogen activator in conditioned medium after 
stimulation of synovial fibroblasts by CTAP-Ill* 












None (n)  
8.6 35.8 (1 )  
4.2 6.2 (1) 
5.2 52.1 (2) 
4.9 24.6 (3) 
87.0 61.0 ( I )  
3.7 53.0 (2) 
4.4 9.7 (2) 
11.8 2 23.8 35.7 ? 29.9 
MNL-CM 
(n) 
81.1 ( I )  
47.1 ( I )  
9.7 (2) 
7.1 (2) 
17.0 ( I )  
51.1 (1 )  
28.7 2 27.9 
- 
* Synovial fibroblasts were cultured in uncoated wells in the pres- 
ence or absence of connective tissue activating peptide 111 (CTAP- 
111. 20 pg/ml) or mononuclear leukocytexonditioned medium 
(MN1,-CM, 1:IO) for 48 hours. Then the stimulants were removed 
and culture in Dulbecco's modified Eagle's medium containing 
lactalbumin hydrolysate (DME-LH) continued for 24 hours. Plas- 
minogen activator activity in 50-pI aliquots of the DME-I,H was 
measured as described in Materials and Methods. Values are % '"I- 
fibrin solubilized, mean :+. SD. 
t OA = osteoarthritis: KA = rheumatoid arthritis: CPPD = calcium 
pyrophosphate deposition disease. 
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Figure 1. Induction of plasminogen activator (PA) secretion in 
synovial fibroblasts by connective tissue activating peptide 111 
(CTAP-111) and mononuclear leukocyte-conditioned medium 
(MNL-CM). Mediators were added to cultures of synovial fibro- 
blasts plated on '"I-fibrin, then PA activity was measured as 
described in Materials and Methods. CTAP-I11 enhanced PA activi- 
ty 24-48 hours after addition to culture. Activation by MNL-CM 
was detected 4 hours after addition to culture. 3 = unstimulated; 0 
= CTAP-111; A = MNL-CM. 
Similar enhancement of PA secretion by CTAP- 
I11 and MNL-CM was observed when enzyme activity 
was measured in fibroblast-conditioned medium (Table 
2). A cell line derived from a patient with pseudogout 
(patient AD) had extremely high basal activity and was 
not further stimulated by CTAP-111 (Table 2). In 1 of 2 
fibroblast lines derived from skin. CTAP-111 induced 
PA activity (not shown). To determine whether a 
phagocytic stimulus could enhance enzyme induction 
by CTAP-111, latex particles were added during culture 
(1-5 x lo2 particleskell); in 3 experiments, PA induc- 
tion was not affected. 
Neither CTAP-I11 nor MNL-CM altered fibro- 
blast survival in culture, although MNL-CM altered 
cellular morphology, as described by Hamilton and 
Slywka ( I  I ) .  Addition of lipopolysaccharide (lo-"- 
lo-' gm/ml) did not stimulate PA secretion, and prein- 
cubation of CTAP-111 with the endotoxin-binding pep- 
tide polymixin B (12) did not prevent induction. These 
experiments suggest that PA induction was not caused 
by endotoxin contamination of the mediator prepara- 
tion (13). 
Delayed induction of increased PA activity. In 5 
experiments using 2 cell lines, fibroblasts were cul- 
tured on '"I-fibrin with assay of enzyme activity 4-48 
hours after stimulation. CTAP-111 stimulated PA se- 
cretion after 24 hours in I experiment and after 48 
hours in 4 experiments. Enhancement of PA secretion 
coincided with increases in glycolysis and glycosamino- 
glycan synthesis in stimulated cultures. This delayed 
induction differed from MNL-CM-induced enzyme 
secretion, which appeared within 4 hours (Figure 1 ) .  
Effects of cycloheximide, actinomycin D, cytosine 
arabinoside, and dexamethasone on PA activity. In 2 
experiments, cycloheximide (1 pglml) reduced PA 
activity by more than 90%, indicating a require- 
ment for continuous protein synthesis for PA secre- 
tion. Cytosine arabinoside ( lOP4M), an inhibitor of 
DNA synthesis, had no effect on PA induction in 
4 experiments. 
In 6 experiments involving 4 cell lines, actino- 
mycin D effects differed. With cell lines from patients 
with osteoarthritis (patient SH) and rheumatoid arthri- 
tis (patient WS), actinomycin D (0.3 pg/ml) abolished 
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Figure. 2. Effcct of dexarnethasone (Dex) on plasminogen activator 
(PA) induction by conrrective tissue actifitinp, peptide 111 (CTAP- 
111). The steroid was added at the same time as the peptide, as 
described in Materials and Methods, then PA activity was assayed 
48 hours later. Actinomycin D (Act D) reversed the dexamethasone 
effect in 2 cell lines. 
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others, derived from patients with rheumatoid arthritis 
(patient EG) and psoriatic arthritis (patient GJ), the 
drug did not prevent PA induction by either stimulus. 
It is possible that these latter lines already contained 
RNA required for PA induction, perhaps because of a 
greater degree of endogenous activation. 
Dexarnethasone reduced PA induction by 
CTAP-111 as well as  by MNL-CM (Figure 2). In 2 cell 
lines (patients GJ and EG), actinomycin D reversed 
the dexamethasone effect, indicating that the drug was 
not toxic to the cells and, consistent with other obser- 
vations (14), that corticosteroid inhibition of PA secre- 
tion required RNA synthesis. 
DISCUSSION 
Plasminogen activator is a neutral protease im- 
plicated in the pathogenesis of chronic inflammation. 
PA itself may be a lymphocyte mitogen (15). In 
activating plasminogen, the enzyme generates degra- 
dative activity with a broad substrate specificity. In 
particular, within the articular space, plasmin can 
directly degrade proteoglycan (16) and activate the 
latent collagenase secreted by synovial cells (17). 
Plasmin can also induce secretion of collagenase (18). 
PA may, by initiating such protease activity, promote 
invasive properties of the synovial pannus, much as 
PA and plasminogen promote invasive properties of 
experimentally transformed fibroblasts (19). 
Numerous immunologic and non-immunologic 
stimuli induce or enhance neutral protease secretion 
by inflammatory and synovial cells. Incubation of 
rabbit synovial fibroblasts with latex particles (20) or 
proteolytic enzymes (18) led to increased secretion of 
PA or collagenase. Interleukin-1, secreted by mononu- 
clear phagocytes under immune stimulation, induced 
collagenase production by adherent synovial cells (21). 
Another monocyte factor, discovered and character- 
ized by Hamilton et  a1 (13), stimulated PA activity of 
human synovial fibroblasts. 
The research reported here places CTAP-111, a 
naturally occurring and chemically characterized me- 
diator, among those stimuli which enhance protease 
activity of synovial fibroblasts. Incubation of synovial 
cells regularly induced increased PA activity. Induc- 
tion of PA was delayed, as are certain other CTAP-III- 
stimulated events, such as glycosaminoglycan secre- 
tion and accelerated glycolysis. Stimulation of enzyme 
secretion by MNL-CM occurred earlier and was usual- 
ly of higher magnitude. Further characterization of the 
extent and regulation of protease induction by CTAP- 
I11 is under investigation. 
Other properties of PA induction in fibroblasts 
by CTAP-I11 resemble those in other target cells by 
other stimuli. PA induction by CTAP-111 was inhibited 
by submicromolar concentrations of dexamethasone. 
The drug affected MNL-CM-stimulated fibroblasts 
similarly (22). Dexamethasone likewise has reduced 
PA secretion in activated murine macrophages and in 
hepatoma cells (14,23). In the present work, inhibition 
of RNA synthesis reversed the steroid effect, again 
similar to dexamethasone inhibition of PA in diverse 
cell types (14,23). As observed by others (1 1,14,24,25), 
PA secretion was reduced by inhibition of protein 
synthesis, but not DNA synthesis. 
It is postulated that CTAP-111-stimulated 
events are chronically and often inappropriately elicit- 
ed “reparative” processes which contribute to the 
proliferative lesions of chronic inflammation (3). This 
report provides evidence that CTAP-I11 within inflam- 
matory sites may also initiate degradative and invasive 
processes. 
Platelets are not known to infiltrate inflamma- 
tory tissues, but platelet degranulation at sites of 
microvascular injury (26) could lead to diffusion of 
CTAP-I11 into synovium. Platelets have also been 
detected in synovial fluid (27,28) where immune com- 
plexes or lymphokines might stimulate degranulation 
(29,30). CTAP-111 antigen levels are elevated in plasma 
in rheumatoid arthritis (31) and the mediator is present 
in rheumatoid synovium and synovial fluid (32,33). It 
is possible that CTAP-111 stimulates, within inflamed 
synovium, the mitotic, metabolic, and proteolytic ac- 
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